Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of KB195 in Urea Cycle Disorder
2018-004842-40Phase 2Completed
- Sponsor
- Kaleido Biosciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of onterodrimer in urea cycle disorder (UCD), sponsored by Kaleido Biosciences. Primary endpoint: Fasting plasma ammonia reduction. Started May 2019; status: completed.
02
Drugs
onterodrimer
03
Conditions
urea cycle disorder (UCD)
Beyond the preview
Go deeper on 2018-004842-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004842-40.